[go: up one dir, main page]

UY36973A - SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES - Google Patents

SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES

Info

Publication number
UY36973A
UY36973A UY0001036973A UY36973A UY36973A UY 36973 A UY36973 A UY 36973A UY 0001036973 A UY0001036973 A UY 0001036973A UY 36973 A UY36973 A UY 36973A UY 36973 A UY36973 A UY 36973A
Authority
UY
Uruguay
Prior art keywords
sol
gel
polymeric compounds
response
methods
Prior art date
Application number
UY0001036973A
Other languages
Spanish (es)
Inventor
R Quesnell Rebecca
Sumitra Rajagopalan
Wilms Baille
Piotr Kujawa
A Zook Christopher
L Huczek Dennis
L Secreast Stephen
Laibin Luo
A Sanders Tammy
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of UY36973A publication Critical patent/UY36973A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Polymers & Plastics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Compuestos poliméricos sol-gel comprendiendo quitosano, polímero hidrófilo, agente de gelificación, ingredientes adicionales opcionales en medio adecuado. El polimérico sol-gel puede formar sello duradero o sólido fuerte en respuesta a estímulos fisiológicos. Usos médicos y veterinarios, métodos y sistemas de administración para reducir o prevenir incidencia de trastorno mamario en animal lechero. Métodos y composiciones de poliméricos sol-gel para crear una barrera física en la superficie del pezón o en el canal o la cisterna del pezón de animal no humano para tratamiento profiláctico de trastornos mamarios, donde el polímero sol-gel crea un sello en respuesta a estímulos fisiológicosSol-gel polymeric compounds comprising chitosan, hydrophilic polymer, gelling agent, optional additional ingredients in suitable medium. The sol-gel polymer can form a durable or strong solid seal in response to physiological stimuli. Medical and veterinary uses, methods and administration systems to reduce or prevent incidence of breast disorder in dairy animals. Methods and compositions of sol-gel polymers to create a physical barrier on the surface of the nipple or in the nipple canal or cistern of a non-human animal for prophylactic treatment of breast disorders, where the sol-gel polymer creates a seal in response to physiological stimuli

UY0001036973A 2015-11-03 2016-11-03 SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES UY36973A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250126P 2015-11-03 2015-11-03
US201662315756P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
UY36973A true UY36973A (en) 2017-06-30

Family

ID=57471981

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036973A UY36973A (en) 2015-11-03 2016-11-03 SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES

Country Status (16)

Country Link
US (2) US10064870B2 (en)
EP (1) EP3370698B1 (en)
JP (1) JP6864001B2 (en)
KR (1) KR102145435B1 (en)
CN (1) CN108601723B (en)
AU (1) AU2016350868B2 (en)
BR (1) BR112018009010B1 (en)
CA (1) CA3002214C (en)
CL (1) CL2018001194A1 (en)
ES (1) ES2907686T3 (en)
MX (1) MX374683B (en)
PL (1) PL3370698T3 (en)
PT (1) PT3370698T (en)
RU (1) RU2761212C2 (en)
UY (1) UY36973A (en)
WO (1) WO2017079216A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
RU2018135961A (en) 2016-03-18 2020-04-20 Министерство Сельского Хозяйства И Сельскохозяйственной Продукции Ее Величества Королевы Канады По Праву METHOD FOR ACCELERATING INVOLUTION AND PREVENTING DIGITAL ANIMAL INFECTIONS ON START-UP
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
KR102359766B1 (en) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 Substituted Indole Compound Derivatives as Dengue Virus Replication Inhibitors
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Substituted indoline derivatives as dengue viral replication inhibitors
JP7123971B2 (en) * 2017-04-20 2022-08-23 ゾエティス・サービシーズ・エルエルシー Veterinary compositions for use in treating mastitis and related methods
JP7203764B2 (en) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド Substituted Indoline Derivatives as Dengue Virus Replication Inhibitors
PE20200342A1 (en) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION
EP3634378A1 (en) * 2017-06-09 2020-04-15 Zoetis Broomhill IP Limited Intramammary veterinary composition
CN109575484A (en) * 2017-09-29 2019-04-05 天津城建大学 Novel galapectite/polyvinyl alcohol composite aerogel and its preparation method and application
US20190167714A1 (en) * 2017-12-01 2019-06-06 Zoetis Services Llc Hydrogel compositions and uses thereof
WO2019141771A1 (en) * 2018-01-18 2019-07-25 Zoetis Broomhill Ip Limited Internal teat sealants and their use in the prevention of bovine mastitis in the dry cow
BR112021008513A2 (en) * 2018-11-22 2021-08-03 Jichi Medical University viscoelastic composition to fix the visual field of the endoscope
WO2020118660A1 (en) * 2018-12-14 2020-06-18 Ecolab Usa Inc. Stable iodine-containing antimicrobial teat dip compositions
CN110437471B (en) * 2019-07-11 2022-02-15 郑州轻工业学院 A kind of viscous composite hydrogel and its preparation method and use
WO2021127423A1 (en) * 2019-12-20 2021-06-24 Veri Nano Inc. Nanostructured binary gel composition and use thereof
CN111012947B (en) * 2019-12-30 2021-11-12 南京财经大学 Injectable and self-healing starch-based hydrogel and preparation method and application thereof
CN111214699A (en) * 2020-01-08 2020-06-02 广州贝奥吉因生物科技股份有限公司 Hydrogel for repairing peripheral nerve injury and preparation method thereof
CN111840212B (en) * 2020-06-18 2023-07-21 余祖功 Nipple blocking agent for non-human animals and preparation method thereof
CN111825858B (en) * 2020-07-02 2023-04-25 南京师范大学 Composite hydrogel based on zwitterions and keratin and preparation method thereof
EP4319819A4 (en) * 2021-04-09 2025-02-26 Colorado School Of Mines RADICALLY CROSS-LINKED ZWITTERIONIC GELS AND USES THEREOF
EP4329790A1 (en) * 2021-04-28 2024-03-06 Mileutis Ltd. Compositions and methods for modulating mammary disorders and conditions
CN113736435B (en) * 2021-10-08 2023-05-12 扬州工业职业技术学院 Nanometer microemulsion plugging agent for drilling fluid and preparation method thereof
CN114539574B (en) * 2022-02-28 2023-06-06 浙江农林大学 Preparation method and application of piezoelectric-triboelectric coupling sensing material
CN115990275A (en) * 2022-10-08 2023-04-21 江苏省人民医院（南京医科大学第一附属医院） A kind of submucosal injection and preparation method thereof
CN115645635A (en) * 2022-10-24 2023-01-31 杭州旸顺医疗科技有限公司 Liquid-phase embolic agent, preparation method and application thereof
CN115804870B (en) * 2022-12-02 2023-12-19 浙江大学 Minimally invasive injection biological stent and manufacturing method and application thereof
WO2024123809A1 (en) * 2022-12-06 2024-06-13 Tricol Biomedical, Inc. Flowable chitosan bioadhesive hemostatic compositions that resist dissolution

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4333484A (en) 1978-08-02 1982-06-08 Philip Morris Incorporated Modified cellulosic smoking material and method for its preparation
AU697045B2 (en) 1995-01-16 1998-09-24 Baxter International Inc. Self-supporting sheet-like material of cross-linked fibrin for preventing post- operative adhesions
ES2183223T5 (en) 1996-12-18 2015-05-07 Bimeda Research & Development Limited Intra-mammary composition for veterinary use that does not contain anti-inflammatory agents
CA2212300A1 (en) * 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
WO2001036000A1 (en) 1999-11-15 2001-05-25 Bio Syntech Canada, Inc. Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
AU1979201A (en) 1999-12-09 2001-06-18 Bio Syntech Canada Inc Mineral-polymer hybrid composition
US20040047892A1 (en) 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
ATE473732T1 (en) 2001-09-10 2010-07-15 Bimeda Res And Dev Ltd BIOSECURITY SYSTEM
KR100474945B1 (en) 2002-01-10 2005-03-10 알앤엘생명과학주식회사 Composition for reducing somatic cell and preventing or treating mastitis of dairy cattle
JP2007500692A (en) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Dispersible pharmaceutical composition for treating mastitis and ear disorders
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
CN1980614B (en) 2004-02-02 2011-12-28 百美达研究与发展有限公司 Device for treating animal papillary ducts
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
DK1836239T3 (en) * 2005-01-13 2009-01-19 Cinv Ag Composite materials containing carbon nanoparticles
WO2006082221A1 (en) * 2005-02-03 2006-08-10 Cinvention Ag Drug delivery materials made by sol/gel technology
US9205046B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8323683B2 (en) 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
WO2007066837A1 (en) 2005-12-06 2007-06-14 Lg Household & Health Care Ltd. Delivery system for tooth whitening component using in situ gelling
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
NZ549249A (en) 2006-08-18 2009-10-30 Univ Massey Methods for reducing the incidence of mastitis by administration of keratin
NZ576223A (en) 2006-10-10 2012-04-27 Wisconsin Alumni Res Found Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
WO2008152444A2 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
US9034348B2 (en) 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
AU2007331071A1 (en) * 2006-12-11 2008-06-19 Mor Research Applications Ltd. Novel injectable chitosan mixtures forming hydrogels
US8153612B2 (en) 2006-12-11 2012-04-10 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
CA2685534A1 (en) 2007-04-30 2008-11-06 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
CN101077377A (en) * 2007-05-09 2007-11-28 史义林 Compound chitosan iodide film coating agent for preventing and controlling mammitis of cow and sheep
US20090081173A1 (en) 2007-08-10 2009-03-26 The Board Of Regents Of The University Of Texas System Methods and compositions involving bacteriophage isolates
GB2461186B (en) * 2008-04-21 2010-09-01 Otonomy Inc Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2349209A2 (en) * 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
LT2369937T (en) * 2008-12-04 2017-02-10 Merial, Inc. Intramammary teat sealant
US20100172889A1 (en) * 2008-12-05 2010-07-08 Catchmark Jeffrey M Degradable biomolecule compositions
WO2010069330A2 (en) 2008-12-16 2010-06-24 Carlsberg A/S Coating of hydroxylated surfaces by gas phase grafting
MX2011006586A (en) 2008-12-19 2011-06-30 Biomimetic Therapeutics Inc Bone grafts with reduced protease activity and methods of selection and use.
WO2011022071A2 (en) 2009-08-20 2011-02-24 The Regents Of The University Of California Cardiac compositions
CN101664381A (en) * 2009-08-21 2010-03-10 天津生机集团股份有限公司 Preparation method of in-situ gel sustained-release preparation for treating Bovine mastitis
CN102125516B (en) * 2010-01-13 2014-03-26 北京大学 Thermo-sensitive in-situ gel pharmaceutical composition
CN103080301B (en) 2010-08-19 2016-10-19 加州大学董事会 Compositions comprising perivascular stem cells and NELL-1 protein
EP2651239A1 (en) 2010-12-16 2013-10-23 Spécialités Pet Food Method for producing highly palatable dry cat food
GB201113606D0 (en) 2011-08-05 2011-09-21 Norbrook Lab Ltd Dual chamber syringe
US20130108670A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
US20130108683A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating partial and full thickness wounds and injuries
WO2014071528A1 (en) 2012-11-09 2014-05-15 Bioastra Technologies Inc. Nanostructured phase change materials for solid state thermal management
RU2521401C1 (en) * 2012-12-07 2014-06-27 ГНУ Краснодарский научно-исследовательский ветеринарный институт Российская академия сельскохозяйственных наук (Краснодарский НИВИ) Agent for prevention of mastitis in dairy cows in dry period
AU2014229557B2 (en) 2013-03-13 2017-12-07 Anteis Sa Peptides for skin rejuvenation and methods of using the same
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014150338A1 (en) * 2013-03-15 2014-09-25 Genzyme Corporation Amine functional polyamides
MX381471B (en) 2013-03-15 2025-03-12 Human Biomolecular Res Institute COMPOSITES AND MATRICES FOR USE IN BONE GROWTH AND REPAIR.
TW201532621A (en) 2013-04-22 2015-09-01 Neocutis Sa Antioxidant compositions and methods of using the same
CN103381139A (en) 2013-05-10 2013-11-06 南京农业大学 In situ gel for astragalus polysaccharide injection and preparation method thereof
MX373718B (en) 2013-09-16 2025-03-05 Zoetis Services Llc ASSEMBLY FOR DELIVERY OF SUBSTANCES SEQUENTIALLY AND ASSOCIATED METHODS
CN104510729A (en) 2013-09-26 2015-04-15 黄永 Animal immune resistance-activating composition of fatty acid and derivatives thereof
CA2963468A1 (en) 2014-10-03 2016-04-07 Cytori Therapeutics, Inc. Use of regenerative cells in mitigating burn progression and improving skin graft incorporation and healing

Also Published As

Publication number Publication date
JP6864001B2 (en) 2021-04-21
JP2018536708A (en) 2018-12-13
US10064870B2 (en) 2018-09-04
PT3370698T (en) 2022-03-02
WO2017079216A1 (en) 2017-05-11
AU2016350868B2 (en) 2022-03-31
MX374683B (en) 2025-03-04
AU2016350868A1 (en) 2018-05-10
US10729698B2 (en) 2020-08-04
BR112018009010A8 (en) 2019-02-26
CA3002214C (en) 2022-01-04
CA3002214A1 (en) 2017-05-11
RU2761212C2 (en) 2021-12-06
MX2018005547A (en) 2018-11-09
RU2018115574A (en) 2019-10-25
CN108601723B (en) 2022-05-17
CL2018001194A1 (en) 2019-05-17
ES2907686T3 (en) 2022-04-26
KR102145435B1 (en) 2020-08-18
BR112018009010A2 (en) 2018-10-30
RU2018115574A3 (en) 2020-03-13
KR20180075646A (en) 2018-07-04
CN108601723A (en) 2018-09-28
BR112018009010B1 (en) 2023-09-26
EP3370698A1 (en) 2018-09-12
PL3370698T3 (en) 2022-04-25
EP3370698B1 (en) 2022-01-26
US20190030043A1 (en) 2019-01-31
US20170119785A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
UY36973A (en) SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES
UY37687A (en) VETERINARY COMPOSITIONS FOR USE IN THE TREATMENT OF MASTITIS AND ASSOCIATED METHODS
CL2018001549A1 (en) Hmos Mix
PH12016502323A1 (en) Combination, composition, and method of administering the combination or composition to animals
WO2015069773A8 (en) Devices and methods for continuous drug delivery via the mouth
CL2017001026A1 (en) Methods and compositions particularly for the treatment of attention deficit disorder.
MX2023000796A (en) PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES.
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
MX2017015250A (en) Formation of cyclosporin a/cyclodextrin nanoparticles.
BR112017005209A2 (en) rorc2 methyl and trifluoromethyl substituted pyrrolopyridine modulating compounds and their use
BR112017026544A2 (en) composition comprising anti-UV agent, anionic crosslinked hydrophilic polymer, surfactant having an ehl of less than or equal to 5 and silicone copolymer
NZ727834A (en) Fast acting orally disintegrating film
IT201800001301A1 (en) Gel formulations for oral administration of drugs, particularly in dysphagia patients
RS57539B1 (en) STERILIZED FLEXIBLE PACKAGING FOR THE RECONSTITUTION AND ADMINISTRATION OF MEDICINAL OR NUTRITIONAL SUBSTANCES SUBMITTED BY INFUSION OR INJECTION BY KAP BY CAP INTO THE BODY OF THE PATIENT
ES2582287R2 (en) Procedure for obtaining and pharmaceutical composition of polymeric nanoparticles for the treatment of neuropathic pain caused by peripheral nerve compression
WO2016040814A3 (en) Disulfide polymers and methods of use
MX372875B (en) ORAL CARE COMPOSITIONS COMPRISING AT LEAST ONE PHOSPHATE/ACRYLATE COPOLYMER AND AT LEAST ONE CATIONIC ACTIVE INGREDIENT.
BR112018015624A2 (en) loxapine oral film dosage form
CL2013002107A1 (en) Use of an aqueous viscoelastic fluid to produce a medicinal product for the surgical treatment of the eye, comprising a) at least one polymer of viscosity increase at a concentration of 0.01-30%, b) a ph value that ranges from 6 to 8.5 and c) an osmolarity that ranges from 200 to 400 mosmol / l.
CL2017002801A1 (en) Hydrogel formulation with moderate adhesion
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
RU2014106575A (en) METHOD FOR PREVENTION OF BLEEDING WITH MYOMECTOMY
EP3423500A4 (en) FINE AND UNIFORM COPOLYMERS OF INORGANIC SALTS OF METHYL-MALEIC ACID VINYL ETHER, AND THEIR USE IN ORAL AND PHARMACEUTICAL CARE APPLICATIONS
IT201700075549U1 (en) DEVICE FOR INCREASING THE CLEANSING OF THE ENDODONTIC SYSTEM IN HUMAN TEETH THROUGH THE USE OF ULTRASOUND.
CL2016000893A1 (en) Intrauterine administration system comprising a construction of a body and two deposits, which comprise a progestogen where the deposits have different rates and release times

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20240112